Trial Profile

Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golimumab (Primary)
Indications Ulcerative colitis
Focus Pharmacokinetics
Acronyms GO-KINETIC

Most Recent Events

01 Jun 2019 Status changed to completed.
24 Oct 2018 Results assessing faecal loss of goli-mumab (n=3) presented at the 26th United European Gastroenterology Week
01 Nov 2017 Results assessing association between systemic exposure of Golimumab during induction therapy and endoscopic response, presented at the 25th United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com